Korea Investment Corp
NTLA icon

Korea Investment Corp’s Intellia Therapeutics NTLA Stock Holding History

Korea Investment Corp’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-58,100
Closed -$1.66M – 693
2018
Q3 		$1.66M Sell
58,100
-9,600
-14% -$279K 0.01% 537
2018
Q2 		$1.85M Buy
+67,700
New +$1.64M 0.01% 614

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Korea Investment Corp's NTLA Position: Q4 2018 in Review

Korea Investment Corp sold out of Intellia Therapeutics (NTLA) in Q4 2018, closing a stake of 58,100 shares — an estimated $1.66M sold.

Korea Investment Corp first reported a position in NTLA in Q2 2018 and held it in 2 quarters. The position peaked at $1.85M in Q2 2018. 141 funds tracked by Wall St. Rank hold NTLA as of Q4 2018.

  • Korea Investment Corp reported no remaining Intellia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Korea Investment Corp sold 58,100 Intellia Therapeutics shares in Q4 2018, an estimated $1.66M.
  • Korea Investment Corp first reported a position in Intellia Therapeutics in Q2 2018 and held it in 2 quarters.
  • Korea Investment Corp's Intellia Therapeutics position peaked at $1.85M in Q2 2018.
  • 141 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2018.

Based on Korea Investment Corp's 13F filing for Q4 2018, filed 13 Feb 2019.